The broad, long-term objective of the project is to validate CaV1.3 voltage-gated calcium (Ca2+) channels and TRPC1 store-operated Ca2+ channels as novel therapeutic targets for treatment of Huntington's disease. Huntington's disease (HD) is an autosomal-dominant and fatal neurodegenerative disorder caused by polyglutamine repeat (polyQ) expansion in the amino-terminal of Huntingtin (Htt) protein. Striatal medium spiny neurons (MSN) are preferentially affected in HD. A number of toxic functions have been assigned to mutant Htt, but exact causes of HD pathology remain unknown and no disease-modifying therapy has been developed. Deranged Ca2+ signaling has been proposed to play a key role in HD pathogenesis. Voltage-gated (VGCCs) and store-operated (SOC) Ca2+ channels are important regulators of neuronal Ca2+ signaling, and recent evidence suggested potential importance of these channels in HD. I propose: 1. To develop the physiological in vitro assay for HD toxicity by establishing co-cultures from cortical and striatal neurons from YAC128 HD mice. 2. To validate the CaV1.3 L-type voltage-gated Ca2+ channel as potential target for HD treatment in vitro and in vivo using genetic methods. 3. To validate the TRPC1 store-operated Ca2+ channel as potential target for HD treatment in vitro and in vivo using genetic methods. 4. To evaluate pharmacological inhibitors of CaV1.3 VGCC and TRPC1-supported SOC channels as potential therapeutic agents for HD treatment in cell culture and whole animal experiments with YAC128 HD mouse model. Validation of CaV1.3 VGCC and TRPC1 SOC channels as novel therapeutic targets for HD will create an opportunity for developing novel therapeutic agents for cure of HD.

Public Health Relevance

The proposed project will have direct and immediate relevance for public health. Huntington's disease (HD) is an incurable genetic disorder that causes enormous suffering. The experiments described in the grant are aimed at validating novel therapeutic targets for treatment of HD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS074376-03
Application #
8704830
Study Section
Special Emphasis Panel (ZRG1-MDCN-P (92))
Program Officer
Sutherland, Margaret L
Project Start
2012-04-01
Project End
2016-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
3
Fiscal Year
2014
Total Cost
$344,334
Indirect Cost
$127,772
Name
University of Texas Sw Medical Center Dallas
Department
Physiology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Poguzhelskaya, Ekaterina; Artamonov, Dmitry; Bolshakova, Anastasia et al. (2014) Simplified method to perform CLARITY imaging. Mol Neurodegener 9:19
Bezprozvanny, Ilya; Hiesinger, Peter Robin (2013) The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol Neurodegener 8:23
Bezprozvanny, Ilya (2013) Bilayer measurement of endoplasmic reticulum Ca2+ channels. Cold Spring Harb Protoc 2013:
Kim, Meewhi (2013) Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues. Prion 7:221-8
Chen, Xi; Wu, Jun; Lvovskaya, Svetlana et al. (2011) Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener 6:81